Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Research output: Contribution to journalArticlepeer-review


  • Cesare Gridelli
  • Filippo de Marinis
  • Jean-Louis Pujol
  • Martin Reck
  • Rodryg Ramlau
  • Barbara Parente
  • Thierry Pieters
  • Jesus Corral
  • Katherine Winfree
  • Symantha Melemed
  • Anna Zimmermann
  • William John
  • Julie Beyrer
  • Nadia Chouaki
  • Carla Visseren-Grul
  • Luis G Paz-Ares

Colleges, School and Institutes


In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.


Original languageEnglish
Pages (from-to)1713-21
Number of pages9
JournalJournal of Thoracic Oncology
Issue number11
Publication statusPublished - 2012

Sustainable Development Goals